Nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, was administrated in advanced refractory biliary tract cancer and 22% CCA patients showed an objective response (Kim et al., 2020). Here, PDCD1 is linked to cholangiocarcinoma.